Your session is about to expire
← Back to Search
Drug-Eluting Stent
XIENCE Skypoint Large Vessel Post Approval Study (SPIRIT XLV PAS Trial)
N/A
Waitlist Available
Research Sponsored by Abbott Medical Devices
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 1 year
Awards & highlights
No Placebo-Only Group
Summary
SPIRIT XLV PAS is a prospective, single arm, multi-center, US and OUS post-approval observational study to evaluate the continued safety and effectiveness of the XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System (EECSS) Large Vessel (LV) sizes (diameter 4.5 mm and 5.0 mm) during commercial use in a real-world setting.
Eligible Conditions
- Coronary Artery Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with Target Lesion Failure (TLF) at 1 year
Side effects data
From 2018 Phase 3 trial • 106 Patients • NCT0154449130%
Diarrhoea
28%
Urinary tract infection
20%
Pyrexia
20%
Headache
20%
Anaemia
19%
Cough
19%
Neutropenia
15%
Vomiting
15%
BK virus infection
15%
Tonsillitis
11%
Hypertension
11%
Nasopharyngitis
11%
Leukopenia
11%
Abdominal pain
11%
Upper respiratory tract infection
11%
Blood creatinine increased
9%
Ear infection
9%
Gastroenteritis
9%
Ear pain
9%
Abdominal pain upper
9%
Rhinitis
9%
Weight decreased
7%
Hypomagnesaemia
7%
Pruritus
7%
Nausea
7%
Bronchitis
7%
Vitamin D deficiency
7%
Tremor
6%
Oropharyngeal pain
6%
Cytomegalovirus viraemia
6%
Cytomegalovirus infection
6%
Pain
6%
Oral herpes
6%
Acidosis
6%
Obesity
6%
Skin papilloma
6%
Sinusitis
6%
Haematuria
4%
Epstein-Barr viraemia
4%
Hypertriglyceridaemia
4%
Epstein-Barr virus infection
4%
Rash
4%
Constipation
4%
Mouth ulceration
4%
Fatigue
4%
Weight increased
4%
Proteinuria
2%
Hypokalaemia
2%
Aphthous ulcer
2%
Cystitis
2%
Influenza
2%
Otitis media
2%
Pharyngitis
2%
Hepatic enzyme increased
2%
Pain in extremity
100%
80%
60%
40%
20%
0%
Study treatment Arm
MMF+sTAC
EVR+rTAC
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent SystemExperimental Treatment1 Intervention
Subjects who were implanted with XIENCE Skypoint Large Vessel Everolimus Eluting Coronary Stent System will be included.
Find a Location
Who is running the clinical trial?
Abbott Medical DevicesLead Sponsor
652 Previous Clinical Trials
416,735 Total Patients Enrolled
103 Trials studying Coronary Artery Disease
131,900 Patients Enrolled for Coronary Artery Disease